Spruce Biosciences' TA-ERT Shows Long-Term Cognitive Stabilization in Sanfilippo Syndrome Type B

Event summary

  • Spruce Biosciences presented long-term data at WORLDSymposium™ showing TA-ERT stabilized cognitive function in 22 MPS IIIB patients over six years.
  • TA-ERT normalized CSF heparan sulfate levels and preserved motor skills compared to untreated natural history patients.
  • Siblings study showed treated patient maintained speech and motor functions while untreated sibling regressed.
  • TA-ERT demonstrated a consistent safety profile across 6,000 doses administered to 22 patients.

The big picture

Spruce Biosciences' data positions TA-ERT as a potential first disease-modifying therapy for Sanfilippo Syndrome Type B, a fatal condition with no current approved treatments. The long-term stabilization of cognitive and motor functions represents a significant advancement in treating this ultra-rare neurological disorder. The company is now focused on advancing through the biologics license application process for potential FDA approval.

What we're watching

Regulatory Pathway
Whether Spruce can secure FDA approval for TA-ERT based on existing clinical data.
Commercialization Strategy
How Spruce plans to address the ultra-rare disease market for MPS IIIB.
Therapeutic Impact
The long-term durability of cognitive and motor function benefits observed in TA-ERT patients.